Early Application of Analytical Tools for Donor Screening and Cellular Starting Material Characterization Help Anticipate and Mitigate Cell Therapy Manufacturing Risk
Tuesday, March 17, 2026 2:15 PM to 2:35 PM · 20 min. (Europe/London)
Cell Therapy Sponsored by LICOR-Bio (Track 3)
Presentation
Information
- Linking donor biology to cellular starting material enables adaptive manufacturing that boosts yield, quality, cost efficiency, and clinical consistency.
- Rapid, automated Accellix testing at collection delivers fast, standardized COAs, tightening blood center–CDMO collaboration and cutting delays, idle time, and failure risk.
